Rituximab tops other disease-modifying tx options in MS

January 9, 2018

(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published online Jan. 8 in JAMA Neurology.

Mathias Granqvist, M.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a using prospectively collected data for patients in Sweden with newly diagnosed RRMS. The effectiveness and drug discontinuation rates of rituximab were compared with those of injectable DMTs, , fingolimod, and natalizumab.

Of the 494 patients, 43.5 percent received an injectable DMT, 17.4 percent dimethyl fumarate, 3.4 percent fingolimod, 10.1 percent natalizumab, 24.3 percent rituximab, and 1.2 percent other DMT. The researchers found that there were pronounced regional preferences, with 81 and 18 percent of patients in Västerbotten and Stockholm, respectively, receiving rituximab. The annual discontinuation rates were 0.03, 0.53, 0.32, 0.38, and 0.29 for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab, respectively. The main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod was continued disease activity; the main reason for discontinuation of natalizumab was positive John Cunningham virus serology results. Compared with injectable DMTs and dimethyl fumarate, the rates of clinical relapse and/or neuroradiologic disease activity were significantly lower for rituximab, with a tendency for lower relapse rates relative to and .

"Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen, which manufactures .

Explore further: Rituximab effective for lupus-associated cytopenia

More information: Abstract/Full Text

Related Stories

Rituximab effective for lupus-associated cytopenia

December 27, 2017
(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

PFS up with obinutuzumab-based Tx in follicular lymphoma

October 5, 2017
(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Adding rituximab to chemo ups event-free survival in ALL

September 20, 2016
(HealthDay)—For young adults with acute lymphoblastic leukemia (ALL), adding rituximab to chemotherapy is associated with increased event-free survival, according to a study published in the Sept. 15 issue of the New England ...

Dimethyl fumarate linked to development of PML

April 9, 2015
(HealthDay)—An active ingredient in some psoriasis and multiple sclerosis medications, dimethyl fumarate, has been linked to two cases of progressive multifocal leukoencephalopathy (PML), according to two letters published ...

Tocilizumab treats rheumatoid arthritis after non-TNFi failure

March 30, 2016
(HealthDay)—For patients with rheumatoid arthritis (RA) and a first non-tumor necrosis factor inhibitor (TNFi) failure, treatment with tocilizumab seems more efficacious than abatacept or rituximab, according to a study ...

Recommended for you

White matter repair and traumatic brain injury

September 20, 2018
Traumatic brain injury (TBI) is a leading cause of death and disability in the U.S., contributing to about 30 percent of all injury deaths, according to the CDC. TBI causes damage to both white and gray matter in the brain, ...

'Gut sense' is hardwired, not hormonal

September 20, 2018
If you've ever felt nauseous before an important presentation, or foggy after a big meal, then you know the power of the gut-brain connection.

Genomic dark matter activity connects Parkinson's and psychiatric diseases

September 20, 2018
Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these specialized cells ...

Full, but still feasting: Mouse study reveals how urge to eat overpowers a signal to stop

September 20, 2018
Almost everyone knows the feeling. You're at a restaurant or a holiday meal, and your stomach is telling you it's full, so logically you know you should stop eating.

Gut branches of vagus nerve essential components of brain's reward and motivation system

September 20, 2018
A novel gut-to-brain neural circuit establishes the vagus nerve as an essential component of the brain system that regulates reward and motivation, according to research conducted at the Icahn School of Medicine at Mount ...

Gambling monkeys help scientists find brain area linked to high-risk behavior

September 20, 2018
Monkeys who learned how to gamble have helped researchers pinpoint an area of the brain key to one's willingness to make risky decisions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.